Mid-follicular LH supplementation in women aged 35-39 years undergoing ICSI cycles: a randomized controlled study

REPRODUCTIVE BIOMEDICINE ONLINE

卷:22

Article

Matorras, R.^1,3  Prieto, B.¹  Exposito, A.¹  Mendoza, R.¹  Crisol, L.¹  Herranz, P.²  Burgues, S.² 

[1] Univ Basque Country, Hosp Cruces, Dept Obstet & Gynecol, Baracaldo, Vizcaya, Spain

[2] Merck Farma & Quim SL, Madrid, Spain

[3] IVI Bilbao, Bilbao, Spain

关键词: ICSI;    implantation;    metaphase II;    pregnancy;    r-HFSH;    r-HLH;   

DOI  :  10.1016/S1472-6483(11)60008-4

来源: Elsevier

【 摘 要 】

This single-centre, randomized, parallel group, comparative study aimed to identify potential benefits of mid-follicular recombinant human LH (r-HLH) supplementation in women aged 35-39 years undergoing ovarian stimulation for intracytoplasmic sperm injection (ICSI). The main endpoint was the number of metaphase II oocytes retrieved. After pituitary suppression with a gonadotrophin-releasing hormone agonist, ovarian stimulation was initiated with recombinant human FSH (r-HFSH; 300-450 IU/day). On stimulation day 6, patients were randomized to receive r-HFSH alone or r-HFSH + r-HLH (r-HLH 150 IU/day) for the remainder of the stimulation period. Final follicular maturation was triggered with 250 mu g of recombinant human chorionic gonadotrophin. After assessing oocyte nuclear maturity, oocyte were fertilized by ICSI and afterwards embryo quality was analyzed. Of the 131 women enrolled, 68 were allocated to r-HFSH alone and 63 to r-HFSH + r-HLH. No significant differences were observed in markers of either oocyte or embryo quality or quantity. However, higher rates of implantation and live birth per started cycle were observed with r-HLH supplementation than with r-HFSH alone. Although additional large studies are required to further investigate these findings, r-HLH supplementation for women aged 35-39 years undergoing ICSI is recommended as it may have a beneficial action on implantation.

【 授权许可】

Free